IPP Bureau
Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion
By IPP Bureau - August 07, 2024
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
India emerging as world-class cost-effective healthcare destination and global pharma leader: Dr. Jitendra Singh
By IPP Bureau - August 07, 2024
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Gland Pharma posts 16% revenue growth in Q1 FY25
By IPP Bureau - August 07, 2024
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Lonza upgrades clinical manufacturing services at Bend site to include bottling and labeling capabilities
By IPP Bureau - August 07, 2024
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Daiichi Sankyo and Merck enter into global agreement for MK-6070
By IPP Bureau - August 07, 2024
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Sucralose safe to use in small doses; reveals MDRF study
By IPP Bureau - August 07, 2024
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Aster DM Healthcare launches Pediatric & Geriatric Emergency Departments at Aster MIMS, Calicut
By IPP Bureau - August 07, 2024
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets
By IPP Bureau - August 06, 2024
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr
By IPP Bureau - August 06, 2024
Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024
Lupin completes successful Phase 3 trials for Lucentis biosimilar
By IPP Bureau - August 06, 2024
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP
By IPP Bureau - August 06, 2024
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
By IPP Bureau - August 06, 2024
Revolutionary technology will further boost OneSource’s scientific services offerings
Vijaya Diagnostic Centre reports Q1 FY25 consolidated PAT at Rs. 31.34 Cr
By IPP Bureau - August 06, 2024
Vijaya Diagnostic Centre has reported total income of Rs. 159.78 crores during the quarter ended June 30, 2024
Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr
By IPP Bureau - August 06, 2024
Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024
Cupid post Q1 FY25 profit at Rs. 8.25 Cr
By IPP Bureau - August 06, 2024
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
